The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical and Pathophysiological Characteristics of Severe Asthma

중증 천식의 임상적, 병태생리적 특징

  • Kim, Sang-Heon (Department of Internal Medicine, Hanyang University College of Medicine)
  • 김상헌 (한양대학교 의과대학 내과학교실)
  • Published : 2012.10.01
⟨ Previous Next ⟩

Abstract

Severe asthma is characterized by poor asthma control and frequent exacerbation despite high degree of medication. Severe asthma leads to not only increased morbidity and mortality but high socioeconomic burden. To date, several research networks have been organized to understand the clinical and pathophysiological characteristics of severe asthma. These groups organized multicenter registries and collected both clinical and biological information. The results of these groups revealed that severe asthma is a very heterogeneous entity, which could not be defined based on a single feature. Various phenotypes of asthma has been identified based on clinical, inflammatory and immune responses. To understand severe asthma more drastically in consideration of many phenotypes, cluster analysis and endotyping severe asthma have been tried. Although uncontrolled inflammation and airway remodeling underlies the development of severe asthma, much is not known about its pathomechanisms. This review discusses the current understanding of the clinical and pathogenic mechanisms of severe asthma based on the recent publications.

Keywords

References

  1. Blakey JD, Wardlaw AJ. What is severe asthma? Clin Exp Allergy 2012;42:617-624. https://doi.org/10.1111/j.1365-2222.2012.03962.x
  2. Kim SH, Kim TW, Kwon JW, et al. Economic costs for adult asthmatics according to severity and control status in Korean Tertiary Hospitals. J Asthma 2012;49:303-309. https://doi.org/10.3109/02770903.2011.641046
  3. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-413. https://doi.org/10.1016/j.jaci.2006.11.639
  4. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-39. https://doi.org/10.1016/S1081-1206(10)61707-3
  5. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma: European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477. https://doi.org/10.1183/09031936.03.00261903
  6. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910-917. https://doi.org/10.1136/thx.2010.153643
  7. Kim TB, Park CS, Bae YJ, Cho YS, Moon HB; COREA Study Group. Factors associated with severity and exacerbation of asthma: a baseline analysis of the cohort for reality and evolution of adult asthma in Korea (COREA). Ann Allergy Asthma Immunol 2009;103:311-317. https://doi.org/10.1016/S1081-1206(10)60530-3
  8. Haselkorn T, Lee JH, Mink DR, Weiss ST; TENOR Study Group. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2008;101:256-263. https://doi.org/10.1016/S1081-1206(10)60490-5
  9. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-813. https://doi.org/10.1016/S0140-6736(06)69290-8
  10. Bel E, ten Brinke A. A rational approach to the management of severe refractory asthma. Treat Respir Med 2005;4: 365-379. https://doi.org/10.2165/00151829-200504060-00002
  11. Wenzel SE, Busse WW; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:14-21. https://doi.org/10.1016/j.jaci.2006.10.025
  12. Lee JH, Haselkorn T, BorishL, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR Study. Chest 2007;132:1882-1889. https://doi.org/10.1378/chest.07-0713
  13. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-1036.
  14. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984. https://doi.org/10.1056/NEJMoa0808991
  15. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993. https://doi.org/10.1056/NEJMoa0805435
  16. Kim SH, Yoon HJ. Use of the exhaled nitric oxide for management of asthma and respiratory diseases. Korean J Med 2008;74:579-586.
  17. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-395. https://doi.org/10.1164/rccm.200903-0392OC
  18. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-1098. https://doi.org/10.1056/NEJMoa1106469
  19. Al-Ramli W, Préfontaine D, Chouiali F, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009;123:1185-1187. https://doi.org/10.1016/j.jaci.2009.02.024
  20. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-323. https://doi.org/10.1164/rccm.200906-0896OC
  21. Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012;185:356-362. https://doi.org/10.1164/rccm.201107-1317PP
  22. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 201242:650-658. https://doi.org/10.1111/j.1365-2222.2011.03929.x
  23. Moore WC, Evans MD, Bleecker ER, et al. Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol 2011;128:328-336. https://doi.org/10.1016/j.jaci.2011.02.042
  24. Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011;183:299-309. https://doi.org/10.1164/rccm.201002-0295OC
  25. Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;125:1028-1036. https://doi.org/10.1016/j.jaci.2010.02.008
  26. Cohen L, E X, Tarsi J, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007;176:138-145. https://doi.org/10.1164/rccm.200607-1062OC
  27. Busacker A, Newell JD Jr, Keefe T, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009;135:48-56. https://doi.org/10.1378/chest.08-0049
  28. Bergeron C, Fukakusa M, Olivenstein R, et al. Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma. J Allergy Clin Immunol 2006;117:703-705. https://doi.org/10.1016/j.jaci.2005.12.1344
  29. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-657. https://doi.org/10.1067/mai.2002.122465
  30. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174:134-141. https://doi.org/10.1164/rccm.200512-1930OC

Cited by

  1. Exhaled Nitric Oxide Measurement for Asthma Management vol.92, pp.5, 2012, https://doi.org/10.3904/kjm.2017.92.5.453